Literature DB >> 16494581

Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis.

Bong-Kyeong Oh1, Young-Joo Kim, Young Nyun Park, Jinsub Choi, Kyung Sik Kim, Chanil Park.   

Abstract

BACKGROUND: Telomerase reverse transcriptase (hTERT) is the rate-limiting determinant of telomerase, which is critical for carcinogenesis. Dysplastic nodules (DNs) appear to be preneoplastic lesions of hepatocellular carcinomas (HCCs). In this study, in order to characterize DNs, hTERT mRNA, hTERT gene dosage, and mRNA for c-myc, a transcriptional activator of hTERT were studied in human multi-step hepatocarcinogenesis.
METHODS: Fifty four hepatic nodules including 5 large regenerative nodules, 14 low-grade DNs, 7 high-grade DNs, 11 DNs with HCC foci and 17 HCCs, 23 livers with chronic hepatitis/cirrhosis, and 6 normal livers were examined. Transcript levels were measured by real-time quantitative RT-PCR and gene dosages by real-time PCR and Southern blotting.
RESULTS: The hTERT mRNA levels increased with the progression of hepatocarcinogenesis, and a significant induction in the transition between low- and high-grade DNs was seen. Most high-grade DNs strongly expressed hTERT mRNA at levels similar to those of HCCs. Twenty-one percent of low-grade DNs had high levels of hTERT mRNA, up to those of high-grade DNs and there was no difference in the pathological features between low-grade DNs with and without increased hTERT mRNA levels. No correlation was found between hTERT mRNA levels, hTERT gene dosage, and c-myc mRNA levels.
CONCLUSIONS: These results suggest that the induction of hTERT mRNA is an important early event and that its measurement by real-time quantitative RT-PCR is a useful tool to detect premalignant/malignant tendencies in hepatic nodules. However, hTERT gene dosage and c-myc expression are not the main mechanisms regulating hTERT expression in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16494581     DOI: 10.1111/j.1572-0241.2006.00532.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Hepatocellular carcinoma (HCC) recurring 10 years after clearance of hepatitis B surface antigen and 20 years after resection of hepatitis B virus-related HCC.

Authors:  Hiroji Shinkawa; Takuya Nakai; Akihiro Tamori; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Masao Ogawa; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Kazuhiro Hirohashi; Kenichi Wakasa; Shoji Kubo
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 2.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 3.  Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.

Authors:  Fabio Grizzi; Barbara Franceschini; Cody Hamrick; Eldo E Frezza; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  J Transl Med       Date:  2007-01-23       Impact factor: 5.531

4.  Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.

Authors:  Mirko Tarocchi; Simone Polvani; Anna Julie Peired; Giada Marroncini; Massimo Calamante; Elisabetta Ceni; Daniela Rhodes; Tommaso Mello; Giuseppe Pieraccini; Alessandro Quattrone; Claudio Luchinat; Andrea Galli
Journal:  J Hepatol       Date:  2014-05-23       Impact factor: 25.083

Review 5.  Genetic alterations in hepatocellular carcinoma: An update.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

6.  Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma.

Authors:  Wenbin Li; Yue Yan; Zongheng Zheng; Qiaohua Zhu; Qian Long; Silei Sui; Meihua Luo; Miao Chen; Yizhuo Li; Yijun Hua; Wuguo Deng; Renchun Lai; Liren Li
Journal:  Cell Death Dis       Date:  2020-11-25       Impact factor: 8.469

Review 7.  Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer.

Authors:  Steffen Heeg
Journal:  Pharmgenomics Pers Med       Date:  2015-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.